









Markets
/
Stocks
/
nasdaq-ekso
/

Ekso Bionics Holdings Inc

EKSO

5.170USD

+0.040+0.78%

Market hours （ET）Quotes delayed by 15 min

13.56MMarket Cap

LossP/E TTM



Ekso Bionics Holdings Inc

5.170

+0.040+0.78%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Ekso Bionics Holdings Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Ekso Bionics Holdings Inc's Score

Industry at a Glance

Industry Ranking

97 / 210

Overall Ranking

215 / 4616

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

34.750

Target Price

+573.45%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Ekso Bionics Holdings Inc Highlights

StrengthsRisks

Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and persons with physical disabilities or impairments. Its products include EksoNR, which is a wearable robotic exoskeleton specifically designed to be used in a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower-limb powered exoskeleton; Ekso Indego Personal is a lightweight powered lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The Company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate and to walk again; assist individuals with a range of upper extremity impairments and allow industrial workers to perform difficult repetitive work for extended periods. Its segments include EksoHealth and EksoWorks.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 38.82% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 17.93M.

Overvalued

The company’s latest PE is -0.95, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 55.84K shares, decreasing 83.57% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 11.96K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 5.63, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 4.23M, representing a year-over-year increase of 2.37%, while its net profit experienced a year-over-year increase of 31.42%.

Score

Industry at a Glance

Previous score

5.63

Change



Financials

6.12

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.07

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.31

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Ekso Bionics Holdings Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 8.58, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -0.95, which is -87.94% below the recent high of -0.11 and -198.30% above the recent low of -2.83.

Score

Industry at a Glance

Previous score

8.58

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 97/210

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Ekso Bionics Holdings Inc is 34.75, with a high of 60.00 and a low of 9.50.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

34.750

Target Price

+577.39%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Ekso Bionics Holdings Inc

EKSO

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 9.14, which is higher than the Healthcare Equipment & Supplies industry's average of 6.77. Sideways: Currently, the stock price is trading between the resistance level at 5.64 and the support level at 4.54, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.18

Change

-0.04

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.007

Neutral

RSI(14)

53.794

Neutral

STOCH(KDJ)(9,3,3)

66.898

Neutral

ATR(14)

0.433

Low Volatility

CCI(14)

63.447

Neutral

Williams %R

35.238

Buy

TRIX(12,20)

0.227

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

5.206

Sell

MA10

5.032

Buy

MA20

5.015

Buy

MA50

4.662

Buy

MA100

4.070

Buy

MA200

2.437

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.39. The latest institutional shareholding proportion is 1.65%, representing a quarter-over-quarter decrease of 89.39%. The largest institutional shareholder is The Vanguard, holding a total of 11.96K shares, representing 0.35% of shares outstanding, with 86.95% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Li (Kecheng)

30.73K

+105.11%

Lathan (Corinna)

25.61K

+159.61%

Cloyd (Mary Ann)

25.23K

+166.00%

Davis (Scott Gerald)

22.27K

+46.23%

Cresset Asset Management, LLC

17.96K

-0.01%

Independent Financial Partners

16.00K

+1500.00%

Scher (Deborah Lafer)

15.75K

Jones (Jason C)

14.90K

+54.55%

Geode Capital Management, L.L.C.

12.07K

-9.06%

The Vanguard Group, Inc.

Star Investors

11.96K

-69.77%

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 2.09, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.81. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.